Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia

Noninvasive evaluation by a new image analysis program

Yasumichi Arai, Nobuyoshi Hirose, Ken Yamamura, Mitsuru Kimura, Akira Murayama, Isamu Fujii, Motoo Tsushima

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Recent clinical studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors are effective in the prevention of cardiovascular events and regression of atherosclerotic lesions evaluated by angiography. In this study, the authors investigated how lipid-lowering therapy effects on the progression of aortic atherosclerosis by using plain and enhanced computed tomography (CT) of the lower abdominal aorta. Twenty-nine hyperlipidemic patients (mean age 61.4 ±7.2 yr) were enrolled in a prospective open-labeled study. All patients underwent baseline CT scanning of abdominal aorta, screening for serum lipid profile and coagulation-fibrinolysis measurement, then treatment with simvastatin was begun. After 2 years, a follow-up CT scan was done and atherosclerotic lesions were compared between baseline and on-treatment scan. In spite of significant improvement of lipid and fibrinolytic profiles by simvastatin administration, mean aortic wall thickening volume (AWV) was increased during observation period. When patients were divided into subgroups by the levels of on-treatment LDL cholesterol (LDL-C), development rate of AWV was more potently suppressed in patients whose on-treatment LDL-C were below 125 mg/dL (median LDL-C). We could not find any associations of coagulation-fibrinolysis measurements with atherosclerotic lesions. In regard to aortic calcification volume (ACV), low levels of total and HDL cholesterol and higher age were associated with aortic calcification at baseline. These results suggest that aggressive treatment with LDL-C below 125 mg/dL may suppress the progression of wall thickening and factors that promote arterial calcifications and those for wall thickening may be different.

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalAngiology
Volume53
Issue number1
Publication statusPublished - 2002

Fingerprint

Abdominal Aorta
Hypercholesterolemia
Atherosclerosis
Lipids
LDL Cholesterol
Simvastatin
Tomography
Fibrinolysis
Therapeutics
HDL Cholesterol
Angiography
Oxidoreductases
Observation
Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia : Noninvasive evaluation by a new image analysis program. / Arai, Yasumichi; Hirose, Nobuyoshi; Yamamura, Ken; Kimura, Mitsuru; Murayama, Akira; Fujii, Isamu; Tsushima, Motoo.

In: Angiology, Vol. 53, No. 1, 2002, p. 57-68.

Research output: Contribution to journalArticle

Arai, Yasumichi ; Hirose, Nobuyoshi ; Yamamura, Ken ; Kimura, Mitsuru ; Murayama, Akira ; Fujii, Isamu ; Tsushima, Motoo. / Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia : Noninvasive evaluation by a new image analysis program. In: Angiology. 2002 ; Vol. 53, No. 1. pp. 57-68.
@article{074f1f6b6844442bbf859f2b3320fc6f,
title = "Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia: Noninvasive evaluation by a new image analysis program",
abstract = "Recent clinical studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors are effective in the prevention of cardiovascular events and regression of atherosclerotic lesions evaluated by angiography. In this study, the authors investigated how lipid-lowering therapy effects on the progression of aortic atherosclerosis by using plain and enhanced computed tomography (CT) of the lower abdominal aorta. Twenty-nine hyperlipidemic patients (mean age 61.4 ±7.2 yr) were enrolled in a prospective open-labeled study. All patients underwent baseline CT scanning of abdominal aorta, screening for serum lipid profile and coagulation-fibrinolysis measurement, then treatment with simvastatin was begun. After 2 years, a follow-up CT scan was done and atherosclerotic lesions were compared between baseline and on-treatment scan. In spite of significant improvement of lipid and fibrinolytic profiles by simvastatin administration, mean aortic wall thickening volume (AWV) was increased during observation period. When patients were divided into subgroups by the levels of on-treatment LDL cholesterol (LDL-C), development rate of AWV was more potently suppressed in patients whose on-treatment LDL-C were below 125 mg/dL (median LDL-C). We could not find any associations of coagulation-fibrinolysis measurements with atherosclerotic lesions. In regard to aortic calcification volume (ACV), low levels of total and HDL cholesterol and higher age were associated with aortic calcification at baseline. These results suggest that aggressive treatment with LDL-C below 125 mg/dL may suppress the progression of wall thickening and factors that promote arterial calcifications and those for wall thickening may be different.",
author = "Yasumichi Arai and Nobuyoshi Hirose and Ken Yamamura and Mitsuru Kimura and Akira Murayama and Isamu Fujii and Motoo Tsushima",
year = "2002",
language = "English",
volume = "53",
pages = "57--68",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term effect of lipid-lowering therapy on atherosclerosis of abdominal aorta in patients with hypercholesterolemia

T2 - Noninvasive evaluation by a new image analysis program

AU - Arai, Yasumichi

AU - Hirose, Nobuyoshi

AU - Yamamura, Ken

AU - Kimura, Mitsuru

AU - Murayama, Akira

AU - Fujii, Isamu

AU - Tsushima, Motoo

PY - 2002

Y1 - 2002

N2 - Recent clinical studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors are effective in the prevention of cardiovascular events and regression of atherosclerotic lesions evaluated by angiography. In this study, the authors investigated how lipid-lowering therapy effects on the progression of aortic atherosclerosis by using plain and enhanced computed tomography (CT) of the lower abdominal aorta. Twenty-nine hyperlipidemic patients (mean age 61.4 ±7.2 yr) were enrolled in a prospective open-labeled study. All patients underwent baseline CT scanning of abdominal aorta, screening for serum lipid profile and coagulation-fibrinolysis measurement, then treatment with simvastatin was begun. After 2 years, a follow-up CT scan was done and atherosclerotic lesions were compared between baseline and on-treatment scan. In spite of significant improvement of lipid and fibrinolytic profiles by simvastatin administration, mean aortic wall thickening volume (AWV) was increased during observation period. When patients were divided into subgroups by the levels of on-treatment LDL cholesterol (LDL-C), development rate of AWV was more potently suppressed in patients whose on-treatment LDL-C were below 125 mg/dL (median LDL-C). We could not find any associations of coagulation-fibrinolysis measurements with atherosclerotic lesions. In regard to aortic calcification volume (ACV), low levels of total and HDL cholesterol and higher age were associated with aortic calcification at baseline. These results suggest that aggressive treatment with LDL-C below 125 mg/dL may suppress the progression of wall thickening and factors that promote arterial calcifications and those for wall thickening may be different.

AB - Recent clinical studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors are effective in the prevention of cardiovascular events and regression of atherosclerotic lesions evaluated by angiography. In this study, the authors investigated how lipid-lowering therapy effects on the progression of aortic atherosclerosis by using plain and enhanced computed tomography (CT) of the lower abdominal aorta. Twenty-nine hyperlipidemic patients (mean age 61.4 ±7.2 yr) were enrolled in a prospective open-labeled study. All patients underwent baseline CT scanning of abdominal aorta, screening for serum lipid profile and coagulation-fibrinolysis measurement, then treatment with simvastatin was begun. After 2 years, a follow-up CT scan was done and atherosclerotic lesions were compared between baseline and on-treatment scan. In spite of significant improvement of lipid and fibrinolytic profiles by simvastatin administration, mean aortic wall thickening volume (AWV) was increased during observation period. When patients were divided into subgroups by the levels of on-treatment LDL cholesterol (LDL-C), development rate of AWV was more potently suppressed in patients whose on-treatment LDL-C were below 125 mg/dL (median LDL-C). We could not find any associations of coagulation-fibrinolysis measurements with atherosclerotic lesions. In regard to aortic calcification volume (ACV), low levels of total and HDL cholesterol and higher age were associated with aortic calcification at baseline. These results suggest that aggressive treatment with LDL-C below 125 mg/dL may suppress the progression of wall thickening and factors that promote arterial calcifications and those for wall thickening may be different.

UR - http://www.scopus.com/inward/record.url?scp=0036168126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036168126&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 57

EP - 68

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 1

ER -